Blog
RSS FeedPosted by Michael Wonder on 09 Sep 2022
Health Canada approves Pfizer-BioNTech COVID-19 vaccine for kids under 5
9 September 2022 - Health Canada approves Pfizer-BioNTech COVID-19 vaccine for kids under 5. ...
Posted by Michael Wonder on 20 Aug 2022
Health Canada approves COVID-19 booster dose for kids 5 to 11
19 August 2022 - The 10 mcg dose can be given at least 6 months after primary series is completed. ...
Posted by Michael Wonder on 15 Jul 2022
Health Canada authorises use of Moderna COVID-19 vaccine in children 6 months to 5 years of age
14 July 2022 - Today, Health Canada authorised the use of the Moderna Spikevax COVID-19 vaccine in children 6 months to ...
Posted by Michael Wonder on 23 Jun 2022
Maviret (glecaprevir/pibrentasvir) approved by Health Canada for paediatric patients with chronic hepatitis C
22 June 2022 - This approval is supported by 98.4 per cent cure rate across this group of patients who ...
Posted by Michael Wonder on 02 Jun 2022
Health Canada OKs Pfizer COVID-19 booster shot for teens ages 16 and 17
1 June 2022 - Canada on Wednesday authorised a single booster shot of Pfizer and partner BioNTech’s COVID-19 vaccine for ...
Posted by Michael Wonder on 01 May 2022
Moderna submits COVID-19 vaccine for kids 5 and under to Health Canada for review
29 April 2022 - Moderna has asked Health Canada to approve its COVID-19 vaccine for children as young as six ...
Posted by Michael Wonder on 20 Apr 2022
Health Canada grants marketing authorisation for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis ages 6 through 11 years with at least one F508del mutation
20 April 2022 - Vertex has submitted this indication to CADTH & INESSS for health technology assessments. ...
Posted by Michael Wonder on 29 Mar 2022
Seqirus receives Health Canada approval for expanded age indication of its cell-based quadrivalent influenza vaccine for people as young as six months
28 March 2022 - Seqirus announced today that it has received Health Canada approval of Flucelvax Quad (influenza vaccine), its cell-based ...
Posted by Michael Wonder on 28 Mar 2022
Dupixent (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation
28 March 2022 - This is the sixth indication for Dupixent in Canada, its second in asthma, and its second in ...
Posted by Michael Wonder on 28 Mar 2022
Health Canada grants marketing authorisation for Kalydeco (ivacaftor) for patients with cystic fibrosis between the ages of 4 months and 18 years with the R117H mutation in the CFTR gene
25 March 2022 - CNW/ - Vertex Pharmaceuticals Canada today announced that Health Canada has granted marketing authorisation for the ...
Posted by Michael Wonder on 17 Mar 2022
Health Canada authorises Moderna's COVID-19 vaccine in children (6-11 years)
17 March 2022 - Announcement follows recent authorisation of the Company's mRNA COVID-19 vaccine in Australia and the European Union ...
Posted by Michael Wonder on 21 Nov 2021
Moderna files for authorisation of its COVID-19 vaccine with Health Canada to include children ages 6-11 years
17 November 2021 - Submission based on Phase 2/3 study of SPIKEVAX in children ages 6 to 11. ...
Posted by Michael Wonder on 27 Oct 2021
Vertex's supplement to a new drug aubmission for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 6-11 accepted for priority review by Health Canada
27 October 2021 - Vertex Pharmaceuticals today announced that its supplement to a new drug submission for Trikafta (elexacaftor/tezacaftor/ivacaftor and ...
Posted by Michael Wonder on 19 Oct 2021
Health Canada receives submission from Pfizer-BioNTech to authorise the use of Comirnaty COVID-19 vaccine in children 5 to 11 years of age
18 October 2021 - Today, Health Canada received a submission from Pfizer-BioNTech seeking an authorisation for the use of its Comirnaty ...
Posted by Michael Wonder on 25 Sep 2021
Vertex's supplement to a new drug submission for Kalydeco (ivacaftor) for patients with cystic fibrosis between the ages of 4 months and 18 years with the R117H mutation in the CFTR gene accepted for priority review by Health Canada
22 September 2021 - Vertex Pharmaceuticals today announced its supplement to a new drug submission for Kalydeco (ivacaftor) has been ...